
Opinion|Videos|February 7, 2025
Therapy Sequencing in CLL
Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on how prior therapy exposure influences the choice of subsequent treatments.
Advertisement
Episodes in this series

- How do you sequence therapies for patients with CLL, and how does prior therapy exposure influence your subsequent choice of treatments?
Advertisement
Related to this article

First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.

David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.

Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
4
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
5




